The role of FDG-PET/TC in the surgical approach of malignant pleural mesothelioma

Lequaglie, Cosimo1 Giudice, Gabriella1 Brega Massone, Pierpaolo2 Della Morte, Aniello1
1 Centro Riferimento Oncologico Regionale, Rionero in Vulture PZ, Italy 2 S. Rita Clinic, Milano, Italy

Background: Approximately 20-30% of patients undergoing explorative thoracotomy because of the inaccurate imaging used for staging in malignant pleural mesothelioma (MPM). FDG-PET/TC scan could help in preoperative staging, in operative evaluation and in postoperative follow-up in MPM.

Methods: Data from patients with pathologically proven, previously untreated, MPM was obtained from a prospective database. All patients underwent FDG-PET/TC scan. Patients were clinically staged using IMIG staging system. Operative selection criteria were: ps 0-1, cStage I-II, epithelial histology, predictive postoperative FEV1>1.0 L and ejection fraction >40%. Videothoracoscopy for diagnosis and for pleurodesis was made in all the cases.

Fifty-five potentially EPP submitted patients (range age of 31-70 years) were observed between 1999 and 2006. Median PET SUV prior surgery in the primary tumor was 6.8 (range 4-16). The same surgeon team operated 33 patients with MPM (21 male - 12 female), with one only thoracotomic approach in 30 cases, 20 right-sided lesions and 13 left-sided.

Twenty-nine patients underwent EPP. 3 exploratory thoracotomies without resection for chest wall or inferior vena cava invasion, and 1 laparoscopy for peritoneal metastases. All T4 or M1 cases were detected by FDG-PET/TC preoperative scan.

Pericardial (n=26) and diaphragmatic (n=29) defects were repaired by PTFE. Twenty-six patients had epithelioid subtype, 3 sarcomatous and 4 biphasics. Sixteen tumors were pStage I-II, 12 pStage III and 4 pStage IV.

Results: Of the 55 patients who had both FDG-PET/TC and surgical procedure only 4 had unresectable tumors. FDG-PET/TC correctly identified 1 unresectable tumor for proven peritoneal metastases. The follow-up study reported a sensibility of 95% with a diagnostic accuracy of 92% regarding the local recurrences or distant metastases. The analysis correlation in patients with high and low SUV and epithelioid and non-epithelioid histotype showed a better prognosis in both low SUV and epithelioid tumor.

Conclusions: FDG-PET/TC appears to give a good support in staging and prognosis in MPM. Furthermore, a systematic use of PET scan could be prevent the recurrence of MPM in follow-up period in EPP submitted patients.

A preliminary comparison between short and long survivors consecutively diagnosed in a large hospital included in the regional population-based mesothelioma registry (Liguria, Italy)

Mencoboni, Manlio1 Montanaro, Fabio2 Bianchelli, Monica2 Tredici, Simona1 Gaibusher, Valentina1 Racchi, Omar1 Faravelli, Bruno1 Pastorino, Giuseppe1 Lazzarotto, Andrea2 Gennaro, Valerio2
1 Oncology Unit “Villa Scassi” Hospital, Genova, Italy 2 Mesothelioma Registry of Liguria (COR Liguria), Descriptive Epidemiology, Epidemiology and Prevention Dept., National Cancer Research Institute (IST), Genova, Italy 3 Pneumology Unit “Villa Scassi” Hospital, Genova, Italy 4 Thoracic Surgery Unit “Villa Scassi” Hospital, Genova, Italy

Background: Malignant pleural mesothelioma (PM) is a highly aggressive tumour; occupational exposure to asbestos is the most common cause of this cancer. Prognosis is often severe, although occasionally it is possible to observe survival times (ST) longer than two years. We do not know exactly whether and to what extent some variables, such as gender, age at diagnosis, cigarette smoking, histology, and occupational exposure, correlate with prognosis.

Aim of this study was to show the differences between long and short survivors according to these variables.

Methods: We retrospectively studied a series of 281 patients (234 men and 47 women) affected by PM consecutively diagnosed in “Villa Scassi” Hospital (Genoa, Italy) from 1994 to 2003 and subsequently deceased; live status was followed up to 2006, 30th June. Cases were systematically recorded by the regional population-based mesothelioma registry (COR Liguria), following inclusion criteria standardized by the national mesothelioma registry (RENAM). Mean age at diagnosis was 68.6 and 70.6 among men and women, respectively, and difference was not statistically significant (n.s.). Cell morphology was ascertained to be epithelioid in 74% of patients, sarcomatoid in 10%, biphasic in 8% and unspecified in 8%. Median overall survival was 12 and 14 months for men and women, respectively (n.s.). On the basis of ST, patients were classified into short (ST < 12 months) and long survivors (ST ≥ 24 months), and a remaining group with intermediate ST (between 12 and 23 months). According to this categorisation, 142 patients resulted to be short survivors (50%), 93 intermediate survivors (33%) and 48 long survivors (17%). The distribution by gender, age at diagnosis, histology, cigarette smoking and occupational exposure within these groups has been investigated by performing ANOVA analysis on continuous variables and Chi square test on categorical ones.

Results: No statistically significant difference in survival experience was detected between men and women. Among women, age at diagnosis, cigarette smoking, histology and occupational exposure had no correlation to survival. Among men, younger age at diagnosis was associated with a better survival, as mean age was 70 years old among short survivors and 66 years old among long survivors (p=0.03). Subjects with epithelioid PM showed a better survival when compared to other morphologies (p=0.05; n.s.). Definite occupational exposure (versus probable or non occupational) was moderately related to a better survival. Cigarette smoking had no correlation with survival.

Conclusions: From this large series of MPM patients, a sub-group of long survivors (ST ≥ 24 months) was identified. This sub-group with a better prognosis, with respect to shorter survivors, showed a younger age at diagnosis and a larger proportion of epithelioid MPM and of definitely occupationally asbestos exposed cases. The analysis of the role of different therapies, as well as other prognostic factors, on survival has been planned.

Copyright © 2007 by the International Association for the Study of Lung Cancer
Surgical Resection for Oral Tongue Cancer Pulmonary Metastases, a Good Choice?

Mochizuki, Takahiro1 Okumura, Sakae2 Yoshida, Junji1 Ishii, Genichiro1 Ishikawa, Yuichi3 Hayashi, Ryuichi3 Kawabata, Kazuyoshi4 Nakagawa, Ken1 Nagai, Kanji1

1 Division of Thoracic Surgery, Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan 2 Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto, Japan 3 Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan 4 Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Koto, Japan 5 Division of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan 6 Department of Head and Neck, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto, Japan

Background: The lung is the most common distant metastasis site from oral tongue cancer (OTC). However, there have been no reports on surgical resection results for pulmonary OTC metastases. The aim of this study was to evaluate surgical resection for OTC pulmonary metastases efficacy.

Methods: Between 1977 and 2003, 23 OTC patients who developed 1 to 3 pulmonary metastases underwent metastasectomy. The clinico-pathologic features and long-term outcomes were examined.

Results: The 14 men and 9 women had a median age at the time of pulmonary metastasectomy of 56 (range; 28-72 years). All 23 patients had advanced squamous cell OTC with regional lymph node involvement or subsequent regional lymph node metastasis. The median tumor-free interval after the initial OTC treatment was 17 months (range: 1-165 months). Five patients had pneumonectomy, three bilobectomy, 13 lobectomy, and two wedge resection. Two patients underwent a second pulmonary metastasectomy. One patient continues to survive, without recurrence at 229 months right now. Twenty-two patients developed systemic metastases. The interval to systemic metastasis recurrence after pulmonary resection ranged from 1 to 17 months (median, 3.5 months) and 21 died of OTC at 9.5 months median (range: 1-26 months) after metastasectomy. One patient was alive with disease at 24 months after metastasectomy but was lost to follow-up.

Conclusions: Most patients who had OTC pulmonary metastasectomy died of the disease within two years. Even for patients with a solitary metastasis, surgical resection for OTC pulmonary metastases is not a recommended treatment option.

Soluble Mesothelin related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison to Asbestos Diseases and Lung Cancer

Muley, Thomas R.1 Meister, Michael A.1 Hoffmann, Hans2 Dienemann, Hendrik1 Herth, Felix J.1 Philipp, Monika3 Schneider, Joachim4

1 Translational Research Unit, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany 2 Dept. of Surgery, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany 3 Dept. of Pneumology, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany 4 Institut und Poliklinik für Arbeits- und Sozialmedizin, University of Giessen, Giessen, Germany

Background: Soluble mesothelin related proteins (SMRP) have been reported as being potential markers for the detection, staging and monitoring of treatment of malignant pleural mesothelioma (MPM). In order to evaluate the diagnostic accuracy, i.e. sensitivity and specificity of a new ELISA test, we investigated SMRP serum concentrations in patients with MPM, primary lung cancer and benign asbestos diseases, with a particular focus on differential diagnosis.

Methods: The study population consisted of 100 newly diagnosed MPM patients. They were compared to 75 patients with severe forms of asbestosis and 139 patients suffering from untreated primary lung cancer. In addition, 29 MPM patient with tumor relapse or progression after initial therapy were included. SMRP serum concentrations were measured by using the newly developed ELISA kit Mesomark™ (Fujirebio Diagnostics, Malvern, USA distributed by CIS bio GmbH, Berlin, Germany). Statistical analyses (Mann-Whitney U-Test, ROC analysis) were performed with SPSS 14.0 (Chicago, Illinois, USA).

Results: SMRP concentrations were found to be significantly higher in patients suffering from MPM in comparison to benign asbestos diseases (p<0.001) or primary lung cancer (p<0.001). The median values (range) were 1.4 (0.2-31.0) nM, 0.9 (0.1-3.3) nM and 0.8 (0-6.0) nM respectively. The highest SMRP concentrations were found in patients with the epithelial subtype of MPM. However, this was not significantly different from the serum concentrations of the sarcomatoid and the biphasic subtypes. SMRP tended to increase with the tumour stages of MPM.

At a cutoff value of 1.6 nM SMRP reached a sensitivity of 42% with a specificity of 95% for benign asbestos diseases. Youden index revealed an optimal cutoff value of 1.35 nM resulting in a sensitivity of 53% and a specificity of 88%. However, SMRP were also increased in 12.9% (cut-off 1.6 nM) or 19.9% (cutoff 1.35nM) of lung cancer patients. Receiver operator characteristics (ROC) curves resulted in an area under curve (AUC) of 0.72 (95%CI:0.66-0.79) for the discrimination between MPM and non-MPM patients (lung cancer and asbestosis). In the 29 MPM patients with relapse/progression after an initial therapy, SMRP levels were found to be significantly higher (Median: 4.2 (0.2-51.0) nM; p<0.001) compared to the 100 MPM patients without prior treatment.

Conclusion: SMRP serum concentration might be an useful measure in the diagnostic characterisation of MPM and for the differentiation between MPM, benign asbestosis and lung cancer patients. In addition, our results indicate that SMRP might be useful in treatment monitoring and follow-up.